Available Clinical Trials

Clinical Research is an integral part of oncology at Bon Secours Richmond Health System. Clinical trials give patients access to the newest and best treatments for cancer. Bon Secours Richmond Health System is proud to provide the same options as leading national cancer centers. Whether it is looking at new surgical or radiation interventions, or giving a brand new medication, We are striving to find better ways to treat, prevent, and manage cancer.

To inquire about participation in a clinical trial, please contact us at (804) 893-8717.

Please see the available, in-progress clinical trials at Bon Secours Richmond Health System. You may filter these results by searching by disease type or keyword.

Search Clinical Trials

Select Category       or   
Displaying All Clinical Trials (1 - 10 of 34)
A011801

The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), …

A021703

RANDOMIZED DOUBLE-BLIND PHASE III TRIAL OF VITAMIN D3 SUPPLEMENTATION IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (SOLARIS)

A171901

Older Non-Small Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy

A191901

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions,”

Alliance A021502

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer …

Alliance A031704

PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED …

Alliance A221805

Duloxetine To Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II To Phase III Study

Alliance Alchemist E4512

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with …

Alliance ALCHEMIST Trials A151216

Receptor (EGFR) Mutant Non‐small Cell Lung Cancer (NSCLC)

AstraZeneca D3615C00001

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as …